LTS Expands Its CDMO Services to Include Ophthalmic Drug Solutions

LTS Enhances CDMO Portfolio with New Ophthalmic Solutions

Introduction
LTS LOHMANN Therapie-Systeme AG (LTS), renowned for its cutting-edge pharmaceutical technologies, has taken a significant step by broadening its Contract Development and Manufacturing Organization (CDMO) services. This expansion targets the burgeoning segment of ophthalmic drug delivery solutions, addressing an essential need within the healthcare sector.

Strategic Expansion
On April 29, 2026, LTS revealed plans to increase its offerings within the ophthalmic realm, utilizing its state-of-the-art facility located in Lakewood, New Jersey. This new venture in CDMO services will initially emphasize the development of clinical manufacturing processes for sterile ophthalmic products packaged in preservative-free multidose devices. LTS aims to leverage its existing expertise in aseptic manufacturing, previously established through the production of nasal sprays and vials, to meet the rigorous regulatory standards demanded by ophthalmic treatments.

Navigating Unique Challenges
Developing effective ophthalmic drug delivery systems entails a unique set of challenges, particularly concerning sterility, efficacy, and patient safety. CEO Bas van Buijtenen highlighted these challenges, underscoring LTS's dedication to overcoming them through its aseptic manufacturing capabilities. He emphasized that the Lakewood facility is perfectly positioned to foster high-quality CDMO services tailored to the ophthalmic sector, setting a new benchmark in drug delivery within North America.

A Comprehensive Approach
LTS's long-term vision includes offering a full spectrum of CDMO services, ranging from formulation development to commercial manufacturing. All processes will adhere to global regulatory guidelines, ensuring compliance with both U.S. market expectations and international standards. This commitment not only positions LTS as a pivotal player in the ophthalmic market but also reaffirms its mission to innovate in drug delivery technologies continuously.

Meeting Market Demand
The expansion of LTS's CDMO services aligns with a growing demand among pharmaceutical and biotech companies seeking a reliable partner for ophthalmic drug delivery solutions. By merging its development expertise with an established sterile manufacturing infrastructure, LTS intends to cultivate long-term partnerships with clients throughout the entire product lifecycle. This strategy reinforces LTS's role as a trusted resource for companies operating within the demanding and specialized landscape of ophthalmic therapies.

Conclusion
LTS's latest developments are reflective of its strategic vision to diversify its service portfolio, catering to the specific demands of the ophthalmic drug delivery market. As the company gears up to serve a broader array of customers and therapeutic needs, it remains steadfast in its mission: We CARE. We CREATE. We DELIVER. By embracing new technologies and processes, LTS is ready to empower the future of drug delivery infrastructure, ensuring patients receive safe and effective therapies.

About LTS Lohmann Therapie-Systeme AG
LTS is dedicated to enhancing patient care and outcomes through innovative drug delivery solutions. The company offers comprehensive development and manufacturing services tailored to the needs of pharmaceutical and biotech companies. Boasting a diverse technology portfolio that includes transdermal patches, oral films, and sterile delivery products, LTS operates globally, committed to leading in drug delivery innovation.

For more information, visit LTS Lohmann Therapie-Systeme AG.